What do systematic reviews say?

Allopurinol vs placebo

Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  RR 1.93 [0.48, 7.8]
  2 studies · 453 participants
  Moderate

Allopurinol vs benzbromarone

Allopurinol showed no clear difference in withdrawal due to adverse events compared with benzbromarone (low certainty).

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  RR 0.8 [0.18, 3.58]
  2 studies · 91 participants
  Low

Allopurinol vs placebo

Allopurinol showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  RR 1.36 [0.61, 3.08]
  2 studies · 453 participants
  Moderate

Vitamin C vs allopurinol

• Dietary supplements for chronic gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Low

Benzbromarone vs allopurinol

Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  RR 3 [0.64, 14.16]
  1 study · 55 participants
  Low

Febuxostat 40 mg/day vs allopurinol

Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 0.61 [0.35, 1.07]
  1 study · 1513 participants
  High

Febuxostat 80 mg/day vs allopurinol

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 0.91 [0.34, 2.4]
  3 studies · 1044 participants
  Moderate

Febuxostat 120 mg/day vs allopurinol

Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.2 [0.7, 1.93]
  3 studies · 1041 participants
  High

Benzbromarone vs allopurinol

Benzbromarone showed no clear difference in withdrawal due to adverse events compared with allopurinol (low certainty).

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  RR 1.25 [0.28, 5.62]
  2 studies · 91 participants
  Low

Probenecid vs allopurinol

The review found no eligible studies for this question.

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Febuxostat 40 mg/day vs allopurinol

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.2 [0.9, 1.7]
  1 study · 1513 participants
  High

Febuxostat 80 mg/day vs allopurinol

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.3 [0.79, 2.1]
  3 studies · 1044 participants
  Moderate

Febuxostat 120 mg/day vs allopurinol

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.6 [0.49, 5]
  3 studies · 1041 participants
  High

Vitamin C vs allopurinol

• Dietary supplements for chronic gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Low

Probenecid vs allopurinol

The review found no eligible studies for this question.

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found